Bob Löwenberg

73.5k total citations · 12 hit papers
534 papers, 35.9k citations indexed

About

Bob Löwenberg is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Bob Löwenberg has authored 534 papers receiving a total of 35.9k indexed citations (citations by other indexed papers that have themselves been cited), including 352 papers in Hematology, 166 papers in Molecular Biology and 110 papers in Oncology. Recurrent topics in Bob Löwenberg's work include Acute Myeloid Leukemia Research (295 papers), Hematopoietic Stem Cell Transplantation (92 papers) and Acute Lymphoblastic Leukemia research (70 papers). Bob Löwenberg is often cited by papers focused on Acute Myeloid Leukemia Research (295 papers), Hematopoietic Stem Cell Transplantation (92 papers) and Acute Lymphoblastic Leukemia research (70 papers). Bob Löwenberg collaborates with scholars based in Netherlands, United States and Germany. Bob Löwenberg's co-authors include Ruud Delwel, Peter J.M. Valk, Alan K. Burnett, Claudia Erpelinck-Verschueren, Gert J. Ossenkoppele, Pieter Sonneveld, Jan J. Cornelissen, Elihu H. Estey, James R. Downing and Miguel Á. Sanz and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Bob Löwenberg

528 papers receiving 35.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

2009 2.4k citations Hartmut Döhner, Elihu H. Estey et al. Blood profile →
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

2003 1.9k citations Elihu H. Estey, Martin S. Tallman et al. Journal of Clinical Oncology profile →
Acute Myeloid Leukemia

1999 1.0k citations Bob Löwenberg, Alan K. Burnett et al. profile →
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia

2004 997 citations Peter J.M. Valk, Roel G.W. Verhaak et al. profile →
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 654 citations Richard A. Larson, Elihu H. Estey et al. Journal of Clinical Oncology profile →
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2008 605 citations Miguel Á. Sanz, David Grimwade et al. Blood profile →
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. profile →
Therapeutic Advances in Acute Myeloid Leukemia

2011 588 citations Bob Löwenberg et al. Journal of Clinical Oncology profile →
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

2010 578 citations Claudia Erpelinck-Verschueren, Peter J.M. Valk et al. profile →
Report of an international working group to standardize response criteria for myelodysplastic syndromes.

2000 524 citations Hagop M. Kantarjian, Bob Löwenberg et al. profile →
Towards precision medicine for AML

2021 174 citations Hartmut Döhner, Bob Löwenberg et al. profile →
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

2022 159 citations Tim Grob, Adil S. A. Al Hinai et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bob Löwenberg Netherlands	89	23.5k	14.3k	8.0k	6.5k	5.9k	534	35.9k
Elihu H. Estey United States	100	27.6k 1.2×	16.0k 1.1×	8.6k 1.1×	8.7k 1.3×	8.7k 1.5×	687	39.7k
Martin S. Tallman United States	92	23.3k 1.0×	14.9k 1.0×	6.6k 0.8×	9.1k 1.4×	7.0k 1.2×	716	34.8k
Marina Konopleva United States	94	15.6k 0.7×	15.8k 1.1×	7.9k 1.0×	4.3k 0.7×	5.9k 1.0×	917	30.5k
Clara D. Bloomfield United States	91	28.5k 1.2×	17.7k 1.2×	6.6k 0.8×	9.6k 1.5×	12.1k 2.1×	406	42.9k
Guillermo Garcia‐Manero United States	106	30.6k 1.3×	17.8k 1.2×	7.5k 0.9×	8.3k 1.3×	14.7k 2.5×	1.5k	44.1k
Andrea Biondi Italy	85	14.9k 0.6×	10.0k 0.7×	5.3k 0.7×	10.2k 1.6×	3.7k 0.6×	655	27.5k
Gerhard Ehninger Germany	78	13.6k 0.6×	6.1k 0.4×	6.5k 0.8×	3.8k 0.6×	5.2k 0.9×	678	25.0k
Francis J. Giles United States	105	20.4k 0.9×	15.0k 1.0×	9.3k 1.2×	4.8k 0.7×	15.8k 2.7×	786	41.9k
James D. Griffin United States	95	12.4k 0.5×	12.8k 0.9×	7.4k 0.9×	2.3k 0.4×	6.3k 1.1×	354	29.7k
Farhad Ravandi United States	90	24.8k 1.1×	13.0k 0.9×	7.5k 0.9×	9.3k 1.4×	10.4k 1.8×	1.3k	34.7k

Countries citing papers authored by Bob Löwenberg

Since Specialization

Citations

This map shows the geographic impact of Bob Löwenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bob Löwenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bob Löwenberg more than expected).

Fields of papers citing papers by Bob Löwenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bob Löwenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bob Löwenberg. The network helps show where Bob Löwenberg may publish in the future.

Co-authorship network of co-authors of Bob Löwenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Bob Löwenberg. A scholar is included among the top collaborators of Bob Löwenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bob Löwenberg. Bob Löwenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grob, Tim, Adil S. A. Al Hinai, Mathijs A. Sanders, et al.. (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 139(15). 2347–2354. 159 indexed citations breakdown →

Chiţu, Dana, Violaine Havelange, Mojca Jongen‐Lavrencic, et al.. (2017). Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15). Blood. 130. 463–463. 5 indexed citations

Dzneladze, Irakli, John F. Woolley, Meong Hi Son, et al.. (2015). INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. Leukemia. 29(7). 1485–1495. 43 indexed citations

Ossenkoppele, Gert J. & Bob Löwenberg. (2014). How I treat the older patient with acute myeloid leukemia. Blood. 125(5). 767–774. 146 indexed citations

Walter, Roland B., Megan Othus, Alan K. Burnett, et al.. (2013). Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood. 121(13). 2424–2431. 78 indexed citations

Vliet, Martin H. van, Jaap Brand, Henk E. Viëtor, et al.. (2013). Detection of CEBPA Double Mutants in Acute Myeloid Leukemia Using a Custom Gene Expression Array. Genetic Testing and Molecular Biomarkers. 17(5). 395–400. 4 indexed citations

Vliet, Martin H. van, Erik Simons, Lars Bullinger, et al.. (2013). Detection of Mutant NPM1 mRNA in Acute Myeloid Leukemia Using Custom Gene Expression Arrays. Genetic Testing and Molecular Biomarkers. 17(4). 295–300. 4 indexed citations

Jonge, Hendrik J.M. de, Peter J.M. Valk, Nic J.G.M. Veeger, et al.. (2010). High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood. 116(10). 1747–1754. 74 indexed citations

Taskesen, Erdogan, Lars Bullinger, Andrea Corbacioglu, et al.. (2010). Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 117(8). 2469–2475. 262 indexed citations

10.

Döhner, Hartmut, Elihu H. Estey, Sergio Amadori, et al.. (2009). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115(3). 453–474. 2350 indexed citations breakdown →

11.

Montesinos, Pau, Juan Bergua, Edo Vellenga, et al.. (2008). Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 113(4). 775–783. 233 indexed citations

12.

Cornelissen, Jan J., Bronno van der Holt, Gregor Verhoef, et al.. (2008). Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 113(6). 1375–1382. 121 indexed citations

13.

Cornelissen, Jan J., Wim L.J. van Putten, Leo F. Verdonck, et al.. (2007). Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood. 109(9). 3658–3666. 345 indexed citations

14.

Raponi, Mitch, Jean‐Luc Harousseau, Jeffrey E. Lancet, et al.. (2007). Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia. Clinical Cancer Research. 13(7). 2254–2260. 52 indexed citations

15.

Erkeland, Stefan J., Roel G.W. Verhaak, Peter J.M. Valk, et al.. (2006). Significance of Murine Retroviral Mutagenesis for Identification of Disease Genes in Human Acute Myeloid Leukemia. Cancer Research. 66(2). 622–626. 19 indexed citations

16.

Erpelinck-Verschueren, Claudia, Gorica Nikoloski, Bert A. van der Reijden, et al.. (2005). ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells. Leukemia. 19(5). 799–805. 35 indexed citations

17.

Greef, Georgine E. de, Wim L.J. van Putten, Marc Boogaerts, et al.. (2004). Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies. British Journal of Haematology. 128(2). 184–191. 44 indexed citations

18.

Löwenberg, Bob, Stefan Suciu, E Archimbaud, et al.. (1998). Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.. Journal of Clinical Oncology. 16(3). 872–881. 218 indexed citations

19.

Löwenberg, Bob & Riccardo Ghio. (1977). An assay for serum cytotoxicity against erythroid precursor cells in pure red cell aplasia.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 27(8). 285–9. 8 indexed citations

20.

Vriesendorp, H. M., et al.. (1976). Influence of genetic resistance and silica particles on survival after bone marrow transplantation.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 8(3). 483–9. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact